title: Nasal potential difference in congenital bilateral absence of the vas deferens.
abstract: Congenital bilateral absence of the vas deferens (CBAVD) is supposed to be due to defective activity of the cystic fibrosis (CF) transmembrane conductance regulator (CFTR) in the genital tract. With the aim of studying CFTR activity in vivo we measured nasal potential difference (NPD) in a group of CBAVD subjects, who were then compared with normal control subjects and CF patients. Sodium transport, measured under basal conditions and after amiloride superinfusion, was normal in almost all CBAVD patients, who had NPD values similar to those of normal control subjects. Chloride transport was studied by measuring NPD during perfusion with a chloride-free solution and isoproterenol. Under these circumstances CBAVD patients as a whole showed normal chloride secretion. However, three subjects with CBAVD had abnormal NPD values. They had either elevated sweat chloride concentrations together with symptoms of mild CF, or compound heterozygosity (DeltaF508/R117H). In conclusion the group of CBAVD patients as a whole presented normal bioelectric properties of nasal epithelium, suggesting normal CFTR activity. In a small subgroup NPD was abnormal, suggesting a diagnosis of CF, later confirmed by elevated sweat chloride concentrations or positive DNA testing. We suggest that CBAVD patients with altered NPD should undergo further clinical follow-up in order to detect possible late complications of CF.
authors.affiliation: Cystic Fibrosis Center, Azienda Ospedaliera Verona, Verona, Italy. upradal@qubisoft.it
authors.forename: U
authors.initials: U
authors.lastname: Pradal
authors.forename: C
authors.initials: C
authors.lastname: Castellani
authors.forename: A
authors.initials: A
authors.lastname: Delmarco
authors.forename: G
authors.initials: G
authors.lastname: Mastella
mesh_terms: D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000328:Adult; D000584:Amiloride / Q000494:pharmacology; D002712:Chlorides / Q000032:analysis / Q000378:metabolism; D003550:Cystic Fibrosis / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics / Q000502:physiology*; D004247:DNA / Q000032:analysis; D004232:Diuretics / Q000494:pharmacology; D004848:Epithelium / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006579:Heterozygote; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D008564:Membrane Potentials / Q000502:physiology*; D009154:Mutation / Q000235:genetics; D009297:Nasal Mucosa / Q000378:metabolism / Q000503:physiopathology*; D012964:Sodium / Q000378:metabolism; D013542:Sweat / Q000737:chemistry / Q000378:metabolism; D014649:Vas Deferens / Q000002:abnormalities*
chemical_list: D000318:Adrenergic beta-Agonists; C505032:CFTR protein, human; D002712:Chlorides; D004232:Diuretics; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D000584:Amiloride; D004247:DNA; D012964:Sodium; D007545:Isoproterenol